For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including ...

Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...

In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is ...

A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...

A new, long-acting injectable to prevent HIV infection could be a “game-changer” in ending the AIDS epidemic, if all who ...

It’s been called the closest the world has ever come to a vaccine against the AIDS virus. The twice-yearly shot was 100% ...